SCHEMBL30775359

SCHEMBL30775359

O=C1NCc2c1cccc2-c1ccc(O)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.55
PIK3CA P42336 2/20 0.55
PIK3CB P42338 2/20 0.55
KDR P35968 13/20 0.52
CLK4 Q9HAZ1 5/20 0.49
PIM1 P11309 5/20 0.49
ROCK1 Q13464 5/20 0.49
DYRK1A Q13627 4/20 0.49
CDK5 Q00535 2/20 0.49
CSNK1A1 P48729 1/20 0.49
LRRK2 Q5S007 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
PIK3CG P48736 1/20 0.48
LTK P29376 1/20 0.47
MST1R Q04912 1/20 0.47
ROCK2 O75116 5/20 0.46
MAP4K4 O95819 4/20 0.46
AURKB Q96GD4 4/20 0.46
STK3 Q13188 3/20 0.46
NTRK3 Q16288 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19608227 0.81 PIK3CD (0.64) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775402 0.81 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775200 0.80 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775186 0.78 PARP10 (0.56) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30543361 0.77 KDR (0.51) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775345 0.77 PIK3CD (0.49) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775183 0.76 CLK4 (0.53) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL29845432 0.76 CLK4 (0.57) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30331758 0.75 PARP10 (0.69) PIK3CDPIK3CAPIK3CBKDRCLK4
SCHEMBL30775282 0.75 KDR (0.58) PIK3CDPIK3CAPIK3CBKDRCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR PIK3CD 1653/4885PIK3CA 1073/4885PIK3CB 1224/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR PIK3CD 1653/4885PIK3CA 1073/4885PIK3CB 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.